Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites
- 20 May 2003
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (19), 2422-2427
- https://doi.org/10.1161/01.cir.0000066908.82782.3a
Abstract
Background— The 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene has been related to cardiovascular disease. Methods and Results— Insulin resistance was measured with a frequently sampled intravenous glucose tolerance test in the Insulin Resistance Atherosclerosis Study (IRAS), and PAI-1 4G/5G promoter genotype was established by allele-specific polymerase chain reaction amplification of genomic DNA. There were 287 subjects with the 4G/4G genotype (18.4%), 691 heterozygote subjects (44.2%), and 586 carriers of the 5G/5G genotype (37.5%). The genotype distribution was different across the 3 ethnic groups ( P =0.001). PAI-1 levels were lower in blacks than in non-Hispanic whites and Hispanics and lower in non-Hispanic whites than in Hispanics (all P =0.0001). Subjects homozygous for the 4G allele had the highest plasma PAI-1, heterozygote subjects were intermediate, and 5G homozygotes had the lowest levels of PAI-1. These patterns remained unaffected by adjustments for age, gender, clinical center, glucose tolerance status, body mass index, waist, triglycerides, and insulin resistance. Multiple linear regression analyses showed that the 4G/5G genotype explained very little of the variation in PAI-1 levels (0.63% in non-Hispanic whites, 0.99% in Hispanics, and 2.37% in blacks), and interaction analyses revealed no significant differences in the relation of circulating PAI-1 levels to the 4G/5G genotype by ethnicity ( P =0.4). Conclusions— We have shown ethnic differences in the PAI-1 4G/5G polymorphism along with corresponding differences in circulating PAI-1 levels. The association of the genotype with PAI-1 levels was seen consistently among all 3 ethnic groups and was unaffected by metabolic covariates, including insulin resistance.Keywords
This publication has 30 references indexed in Scilit:
- The 4G/5G promotor polymorphism of the plasminogen activator inhibitor‐1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patientsClinical Cardiology, 2001
- Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart diseaseAtherosclerosis, 2001
- Effects of Cigarette Smoking, Diabetes, High Cholesterol, and Hypertension on All-Cause Mortality and Cardiovascular Disease Mortality in Mexican Americans: The San Antonio Heart StudyAmerican Journal of Epidemiology, 1996
- The Insulin Resistance Atherosclerosis Study (IRAS): Objectives, design, and recruitment resultsAnnals of Epidemiology, 1995
- Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) geneFibrinolysis, 1995
- Expression of PAI-1, t-PA and u-PA in cultured human umbilical vein endothelial cells derived from racial groupsThrombosis Research, 1995
- The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistanceMetabolism, 1993
- Diabetes and coronary heart disease risk in Mexican AmericansAnnals of Epidemiology, 1992
- Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1Metabolism, 1990
- Noninsulin‐Dependent diabetes mellitus in black and white AmericansDiabetes/Metabolism Research and Reviews, 1990